These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 36213654)

  • 1. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence.
    Visvabharathy L; Orban ZS; Koralnik IJ
    Front Med (Lausanne); 2022; 9():1003103. PubMed ID: 36213654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.
    Geng LN; Bonilla H; Hedlin H; Jacobson KB; Tian L; Jagannathan P; Yang PC; Subramanian AK; Liang JW; Shen S; Deng Y; Shaw BJ; Botzheim B; Desai M; Pathak D; Jazayeri Y; Thai D; O'Donnell A; Mohaptra S; Leang Z; Reynolds GZM; Brooks EF; Bhatt AS; Shafer RW; Miglis MG; Quach T; Tiwari A; Banerjee A; Lopez RN; De Jesus M; Charnas LR; Utz PJ; Singh U
    JAMA Intern Med; 2024 Sep; 184(9):1024-1034. PubMed ID: 38848477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
    LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP
    BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.
    Thaweethai T; Jolley SE; Karlson EW; Levitan EB; Levy B; McComsey GA; McCorkell L; Nadkarni GN; Parthasarathy S; Singh U; Walker TA; Selvaggi CA; Shinnick DJ; Schulte CCM; Atchley-Challenner R; Alba GA; Alicic R; Altman N; Anglin K; Argueta U; Ashktorab H; Baslet G; Bassett IV; Bateman L; Bedi B; Bhattacharyya S; Bind MA; Blomkalns AL; Bonilla H; Brim H; Bush PA; Castro M; Chan J; Charney AW; Chen P; Chibnik LB; Chu HY; Clifton RG; Costantine MM; Cribbs SK; Davila Nieves SI; Deeks SG; Duven A; Emery IF; Erdmann N; Erlandson KM; Ernst KC; Farah-Abraham R; Farner CE; Feuerriegel EM; Fleurimont J; Fonseca V; Franko N; Gainer V; Gander JC; Gardner EM; Geng LN; Gibson KS; Go M; Goldman JD; Grebe H; Greenway FL; Habli M; Hafner J; Han JE; Hanson KA; Heath J; Hernandez C; Hess R; Hodder SL; Hoffman MK; Hoover SE; Huang B; Hughes BL; Jagannathan P; John J; Jordan MR; Katz SD; Kaufman ES; Kelly JD; Kelly SW; Kemp MM; Kirwan JP; Klein JD; Knox KS; Krishnan JA; Kumar A; Laiyemo AO; Lambert AA; Lanca M; Lee-Iannotti JK; Logarbo BP; Longo MT; Luciano CA; Lutrick K; Maley JH; Mallett G; Marathe JG; Marconi V; Marshall GD; Martin CF; Matusov Y; Mehari A; Mendez-Figueroa H; Mermelstein R; Metz TD; Morse R; Mosier J; Mouchati C; Mullington J; Murphy SN; Neuman RB; Nikolich JZ; Ofotokun I; Ojemakinde E; Palatnik A; Palomares K; Parimon T; Parry S; Patterson JE; Patterson TF; Patzer RE; Peluso MJ; Pemu P; Pettker CM; Plunkett BA; Pogreba-Brown K; Poppas A; Quigley JG; Reddy U; Reece R; Reeder H; Reeves WB; Reiman EM; Rischard F; Rosand J; Rouse DJ; Ruff A; Saade G; Sandoval GJ; Santana JL; Schlater SM; Sciurba FC; Shepherd F; Sherif ZA; Simhan H; Singer NG; Skupski DW; Sowles A; Sparks JA; Sukhera FI; Taylor BS; Teunis L; Thomas RJ; Thorp JM; Thuluvath P; Ticotsky A; Tita AT; Tuttle KR; Urdaneta AE; Valdivieso D; VanWagoner TM; Vasey A; Verduzco-Gutierrez M; Wallace ZS; Ward HD; Warren DE; Weiner SJ; Welch S; Whiteheart SW; Wiley Z; Wisnivesky JP; Yee LM; Zisis S; Horwitz LI; Foulkes AS;
    JAMA; 2023 Jun; 329(22):1934-1946. PubMed ID: 37278994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
    J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and determinants of post-acute sequelae after SARS-CoV-2 infection (Long COVID) among adults in Mexico during 2022: a retrospective analysis of nationally representative data.
    Bello-Chavolla OY; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Fernández-Chirino L; Basile-Alvarez MR; Sánchez-Castro P; Núñez-Luna A; Antonio-Villa NE
    Lancet Reg Health Am; 2024 Feb; 30():100688. PubMed ID: 38327277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating viral and autoimmune T cell responses associated with post-acute sequelae of COVID-19.
    Williams GP; Yu ED; Shapiro K; Wang E; Freuchet A; Frazier A; Lindestam Arlehamn CS; Sette A; da Silva Antunes R
    Hum Immunol; 2024 May; 85(3):110770. PubMed ID: 38433036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19.
    Fleischer M; Szepanowski F; Mausberg AK; Asan L; Uslar E; Zwanziger D; Volbracht L; Stettner M; Kleinschnitz C
    Ther Adv Neurol Disord; 2024; 17():17562864241229567. PubMed ID: 38348267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection.
    Patterson BK; Francisco EB; Yogendra R; Long E; Pise A; Rodrigues H; Hall E; Herrera M; Parikh P; Guevara-Coto J; Triche TJ; Scott P; Hekmati S; Maglinte D; Chang X; Mora-Rodríguez RA; Mora J
    Front Immunol; 2021; 12():746021. PubMed ID: 35082777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies.
    Peluso MJ; Anglin K; Durstenfeld MS; Martin JN; Kelly JD; Hsue PY; Henrich TJ; Deeks SG
    Pathog Immun; 2022; 7(1):95-103. PubMed ID: 35800257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long COVID or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and the Urgent Need to Identify Diagnostic Biomarkers and Risk Factors.
    Parums DV
    Med Sci Monit; 2024 Sep; 30():e946512. PubMed ID: 39289865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations.
    Cohen AK; Jaudon TW; Schurman EM; Kava L; Vogel JM; Haas-Godsil J; Lewis D; Crausman S; Leslie K; Bligh SC; Lizars G; Davids JD; Sran S; Peluso MJ; McCorkell L
    Res Sq; 2023 Sep; ():. PubMed ID: 37790297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC).
    Sherif ZA; Gomez CR; Connors TJ; Henrich TJ; Reeves WB;
    Elife; 2023 Mar; 12():. PubMed ID: 36947108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological post-acute sequelae of SARS-CoV-2 infection.
    Takao M; Ohira M
    Psychiatry Clin Neurosci; 2023 Feb; 77(2):72-83. PubMed ID: 36148558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
    Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
    Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma proteomics show altered inflammatory and mitochondrial proteins in patients with neurologic symptoms of post-acute sequelae of SARS-CoV-2 infection.
    Hanson BA; Visvabharathy L; Orban ZS; Jimenez M; Batra A; Liotta EM; DeLisle RK; Klausner JD; Cohen P; Padhye AS; Tachas G; Koralnik IJ
    Brain Behav Immun; 2023 Nov; 114():462-474. PubMed ID: 37704012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low growth hormone secretion associated with post-acute sequelae SARS-CoV-2 infection (PASC) neurologic symptoms: A case-control pilot study.
    Wright TJ; Pyles RB; Sheffield-Moore M; Deer RR; Randolph KM; McGovern KA; Danesi CP; Gilkison CR; Ward WW; Vargas JA; Armstrong PA; Lindsay SE; Zaidan MF; Seashore J; Wexler TL; Masel BE; Urban RJ
    Mol Cell Endocrinol; 2024 Jan; 579():112071. PubMed ID: 37816478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings.
    Sneller MC; Liang CJ; Marques AR; Chung JY; Shanbhag SM; Fontana JR; Raza H; Okeke O; Dewar RL; Higgins BP; Tolstenko K; Kwan RW; Gittens KR; Seamon CA; McCormack G; Shaw JS; Okpali GM; Law M; Trihemasava K; Kennedy BD; Shi V; Justement JS; Buckner CM; Blazkova J; Moir S; Chun TW; Lane HC
    Ann Intern Med; 2022 Jul; 175(7):969-979. PubMed ID: 35605238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein.
    Visvabharathy L; Hanson BA; Orban ZS; Lim PH; Palacio NM; Jimenez M; Clark JR; Graham EL; Liotta EM; Tachas G; Penaloza-MacMaster P; Koralnik IJ
    Front Immunol; 2023; 14():1155770. PubMed ID: 37313412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.